ATLANTIC STUDY MEDICAL DIRECTIVE – YORK FINAL

An Advanced Care Paramedic may provide the treatment prescribed in this medical directive if certified and authorized

INDICATIONS

Patient with a confirmed acute STEMI

CONDITIONS

Brilinta (Ticagelor)

AGE:	≥ 18 years of age
LOA:	unaltered
HR:	N/A
RR:	N/A
SBP:	N/A
Other:	Onset of ischemic symptoms ≥ 30 min and < 6 hours
	Informed consent received and signed
	New, persistent ST elevation of ≥ 1 mm in 2 or more contiguous leads

CONTRAINDICATIONS

Brilinta (Ticagelor)

Allergy or sensitivity to Ticagrelor

SBP < 80 mmHg

Known pregnancy or lactation, or women of child bearing potential (< 1 year post menopause or not surgically sterile)

LBBB or ventricular paced rhythms

Current use of any of the following medications:

- Antifungals, specifically ketoconazole, itraconazole, voriconazole.
- Macrolide antibiotics specifically telithromycin, clarithromycin
- Antidepressant medication nefazadone,
- HIV related antiretroviral agents specifically: ritonavir, saquinavir, nelfinavir, indinavir, atanazavir
- Antiplatelet agents specifically Ticagrelor, Clopidogrel, Prasugrel, Ticlopidine, Dipyridamole Cilostazol
- Any non-steroidal anti-inflamatory drug (ie Ibuprofen), or oral anticoagulant (ie warfarin)

More than one liter daily intake of grapefruit juice.

Active bleeding or history of previous intracranial bleeding

Moderate to severe liver disease

Planned surgery in the next 30 days

Any of the following conditions in the absence of a functioning pacemaker: known Sick Sinus Syndrome, 2nd or 3rd degree AV blocks or documented syncope of bradycardic origin

Patient on dialysis

Known Anemia or low platelet count

Active cancer

Southlake / York EMS staff or employee of AstraZeneca

Participation in another clinical trial in the last 30 days

TREATMENT

Obtain ***12-lead ECG acquisition:***

Confirm STEMI

Obtain ***informed consent:***

Read the short informed consent form and gain written acceptance from the patient

Administer ***first dose of study drug administration:***

Administer first two (2) tablets from the study pack

Perform ***bypass:***

Transport direct to cath lab at Southlake Regional Health Centre

Perform a ***patch to the receiving department:***

Call 905-895-4521 ext 7777
To activate a code STEMI and Ticagrelor study patient enrollment

Administer ***second dose of study drug administration:***

On arrival Southlake Cath lab, administer the next two (2) tablets from the study pack

Obtain ***12-lead ECG acquisition:***

Obtain a second diagnostic ECG prior to transfer of care

CLINICAL CONSIDERATIONS

This study directive does not exclude care provided within the Cardiac Ischemia Medical Directive.

This study directive builds upon the STEMI bypass directive for York Region. Patients with ischemic pain beyond 6 hours but less than 12 hours may still be bypassed, but not enrolled in the study.

On arrival at the Cath Lab, the remainder of the study pack will be turned over to the receiving staff.

Transmitting the 12 lead to Southlake and patching to the interventional cardiologist remain as options .